> For the complete documentation index, see [llms.txt](https://help.bioinsight.illumina.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation/str-loci-annotated-with-gnomad-pathogenicity-data.md).

# STR loci annotated with gnomAD pathogenicity data

Emedgene annotates STR variants at the loci on this page with the repeat-count ranges that gnomAD defines as pathogenic for each locus. The annotation covers GRCh38 and GRCh37 cases.

***

## gnomAD STR loci (v100.41+)

Table 1 lists the gnomAD loci that Emedgene annotates on v100.41 and later, with the repeat-count range for each significance class.

The start positions and repeat-count ranges are the values Emedgene uses. The other columns are from gnomAD STR release 2025\_03\_17. Where Emedgene's value differs from gnomAD, a footnote gives the gnomAD value.

**Table 1. STR loci annotated with gnomAD data (v100.41 and later).**

<table data-header-hidden="false" data-header-sticky data-full-width="true"><thead><tr><th width="43" data-type="number">№</th><th width="90">STR locus</th><th width="128">Genomic region (GRCh38)</th><th width="99">Associated condition(s)</th><th width="76">Inheritance mode</th><th width="100">Repeat unit</th><th width="98">Benign</th><th width="96">VUS</th><th width="98">Other</th><th width="129">Pathogenic</th></tr></thead><tbody><tr><td>1</td><td><em>ABCD3</em></td><td>1:94418421-94418442</td><td>Oculopharyngodistal myopathy (OPDM)</td><td>AD</td><td>GCC</td><td>0–44</td><td>N/A</td><td>45–117</td><td>≥118</td></tr><tr><td>2</td><td><em>AFF2</em></td><td>X:148500631-148500691</td><td>FRAXE mental retardation (FRAXE)</td><td>XR</td><td>GCC</td><td>0–39</td><td>N/A</td><td>40–199</td><td>≥200</td></tr><tr><td>3</td><td><em>AFF3</em></td><td>2:100104798-100104822</td><td>N/A</td><td>N/A</td><td>GCC</td><td>0–20<sup>a</sup></td><td>N/A</td><td>21–299<sup>a</sup></td><td>≥300<sup>a</sup></td></tr><tr><td>4</td><td><em>AR</em></td><td>X:67545316-67545385</td><td>Spinal and bulbar muscular atrophy (SBMA)</td><td>XR</td><td>GCA</td><td>0–34<sup>b</sup></td><td>N/A</td><td>35–37<sup>b</sup></td><td>≥38</td></tr><tr><td>5</td><td><em>ARX_1</em></td><td>X:25013649-25013697</td><td>Developmental and epileptic encephalopathy 1 (DEE1); X-linked mental retardation with or without seizures (MRXARX)</td><td>XR</td><td>NGC</td><td>0–16</td><td>N/A</td><td>N/A</td><td>≥17<sup>c</sup></td></tr><tr><td>6</td><td><em>ARX_2</em></td><td>X:25013529-25013565</td><td>Developmental and epileptic encephalopathy 1 (DEE1); Partington syndrome (PRTS); X-linked mental retardation with or without seizures (MRXARX)</td><td>XR</td><td>NGC</td><td>0–12</td><td>N/A</td><td>13–19</td><td>≥20<sup>d</sup></td></tr><tr><td>7</td><td><em>ATN1</em></td><td>12:6936716-6936773</td><td>Dentatorubral-pallidoluysian atrophy (DRPLA)</td><td>AD</td><td>CAG</td><td>0–35</td><td>N/A</td><td>36–47</td><td>≥48</td></tr><tr><td>8</td><td><em>ATXN1</em></td><td>6:16327633-16327723</td><td>Spinocerebellar ataxia 1 (SCA1)</td><td>AD</td><td>TGC</td><td>0–35</td><td>36–38</td><td>N/A</td><td>≥39</td></tr><tr><td>9</td><td><em>ATXN10</em></td><td>22:45795354-45795424</td><td>Spinocerebellar ataxia 10 (SCA10)</td><td>AD</td><td>ATTCT</td><td>0–29<sup>e</sup></td><td>30–799</td><td>N/A</td><td>≥800</td></tr><tr><td>10</td><td><em>ATXN2</em></td><td>12:111598949-111599018</td><td>Spinocerebellar ataxia 2 (SCA2)</td><td>AD</td><td>GCT</td><td>0–28<sup>f</sup></td><td>29–34<sup>f</sup></td><td>N/A</td><td>≥35</td></tr><tr><td>11</td><td><em>ATXN3</em></td><td>14:92071009-92071040<sup>g</sup></td><td>Spinocerebellar ataxia 3 (SCA3)</td><td>AD</td><td>CTG</td><td>0–44</td><td>45–55</td><td>56–59<sup>g</sup></td><td>≥60<sup>g</sup></td></tr><tr><td>12</td><td><em>ATXN7</em></td><td>3:63912684-63912714</td><td>Spinocerebellar ataxia 7 (SCA7)</td><td>AD</td><td>GCA</td><td>0–27<sup>h</sup></td><td>34–36</td><td>28–33<sup>h</sup></td><td>≥37</td></tr><tr><td>13</td><td><em>ATXN8OS</em></td><td>13:70139383-70139428</td><td>Spinocerebellar ataxia 8 (SCA8)</td><td>AD</td><td>CTG</td><td>0–37<sup>i</sup></td><td>38–70<sup>i</sup></td><td>N/A</td><td>≥71</td></tr><tr><td>14</td><td><em>BCLAF3</em></td><td>X:19990922-19990973</td><td>N/A</td><td>N/A</td><td>CCG</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>15</td><td><em>BEAN1</em></td><td>16:66490398-66490453</td><td>Spinocerebellar ataxia 31 (SCA31)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–109</td><td>≥110</td></tr><tr><td>16</td><td><em>C11ORF80</em></td><td>11:66744819-66744843</td><td>N/A</td><td>N/A</td><td>GGC</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>17</td><td><em>C9ORF72</em></td><td>9:27573528-27573546</td><td>Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 (FTDALS1)</td><td>AD</td><td>GGCCCC</td><td>0–23</td><td>N/A</td><td>24–30</td><td>≥31</td></tr><tr><td>18</td><td><em>CACNA1A</em></td><td>19:13207858-13207897</td><td>Spinocerebellar ataxia 6 (SCA6)</td><td>AD</td><td>CTG</td><td>0–18</td><td>19–20<sup>j</sup></td><td>N/A</td><td>≥21<sup>j</sup></td></tr><tr><td>19</td><td><em>CBL</em></td><td>11:119206289-119206322</td><td>N/A</td><td>N/A</td><td>CGG</td><td>0–79<sup>a</sup></td><td>80–100<sup>a</sup></td><td>N/A</td><td>≥101<sup>a</sup></td></tr><tr><td>20</td><td><em>CNBP</em></td><td>3:129172576-129172656</td><td>Myotonic dystrophy 2 (DM2)</td><td>AD</td><td>CAGG</td><td>0–26<sup>k</sup></td><td>N/A</td><td>27–74<sup>k</sup></td><td>≥75<sup>k</sup></td></tr><tr><td>21</td><td><em>COMP</em></td><td>19:18786034-18786049</td><td>Multiple epiphyseal dysplasia (EDM1); Pseudoachondroplasia (PSACH)</td><td>AD</td><td>GTC</td><td>N/A</td><td>N/A</td><td>0–5</td><td>≥6<sup>l</sup></td></tr><tr><td>22</td><td><em>CSNK1E</em></td><td>22:38317282-38317306</td><td>N/A</td><td>N/A</td><td>GCC</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>23</td><td><em>CSTB</em></td><td>21:43776443-43776479</td><td>Progressive myoclonic epilepsy type 1 (EPM1)</td><td>AR</td><td>CGCGGGGCGGGG</td><td>0–3</td><td>N/A</td><td>4–29</td><td>≥30</td></tr><tr><td>24</td><td><em>DAB1</em></td><td>1:57367043-57367118</td><td>Spinocerebellar ataxia 37 (SCA37)</td><td>AD</td><td>AAAAT</td><td>0–30<sup>m</sup></td><td>N/A</td><td>N/A</td><td>≥31</td></tr><tr><td>25</td><td><em>DIP2B</em></td><td>12:50505001-50505022</td><td>Mental retardation, FRA12A type (MRFRA12A)</td><td>AD</td><td>GGC</td><td>0–23</td><td>N/A</td><td>24–272</td><td>≥273</td></tr><tr><td>26</td><td><em>DMD</em></td><td>X:31284557-31284605</td><td>N/A</td><td>N/A</td><td>TTC</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>27</td><td><em>DMPK</em></td><td>19:45770204-45770264</td><td>Myotonic dystrophy 1 (DM1)</td><td>AD</td><td>CAG</td><td>0–34</td><td>35–49</td><td>N/A</td><td>≥50</td></tr><tr><td>28</td><td><em>EIF4A3</em></td><td>17:80147059-80147139</td><td>Richieri-Costa-Pereira syndrome (RCPS)</td><td>AR</td><td>CCTCGCTGTGCCGCTGCCGA</td><td>0–12<sup>n</sup></td><td>N/A</td><td>13<sup>n</sup></td><td>≥14</td></tr><tr><td>29</td><td><em>EP400</em></td><td>12:132062524-132062611</td><td>Cerebellar ataxia</td><td>AD</td><td>CAG</td><td>N/A</td><td>N/A</td><td>0–69</td><td>≥70</td></tr><tr><td>30</td><td><em>FAM193B</em></td><td>5:177554489-177554531</td><td>Oculopharyngodistal myopathy (OPDM)</td><td>AD</td><td>CGC</td><td>N/A</td><td>N/A</td><td>0–189</td><td>≥190</td></tr><tr><td>31</td><td><em>FGF14</em></td><td>13:102161576-102161724<sup>o</sup></td><td>Spinocerebellar ataxia 27B (SCA27B)</td><td>AD</td><td>AAG</td><td>0–179<sup>o</sup></td><td>250–319<sup>o</sup></td><td>180–249<sup>o</sup></td><td>≥320</td></tr><tr><td>32</td><td><em>FMR1</em></td><td>X:147912050-147912110</td><td>Fragile X syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)</td><td>XD</td><td>CGG</td><td>0–40<sup>p</sup></td><td>41–54</td><td>N/A</td><td>≥55<sup>p</sup></td></tr><tr><td>33</td><td><em>FOXL2</em></td><td>3:138946020-138946062</td><td>Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES)</td><td>AD</td><td>NGC</td><td>0–14</td><td>N/A</td><td>N/A</td><td>≥15</td></tr><tr><td>34</td><td><em>FRA10AC1</em></td><td>10:93702522-93702546</td><td>N/A</td><td>N/A</td><td>CCG</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>35</td><td><em>FXN</em></td><td>9:69037286-69037304</td><td>Friedreich ataxia (FRDA)</td><td>AR</td><td>GAA</td><td>0–33</td><td>N/A</td><td>34–55<sup>q</sup></td><td>≥56<sup>q</sup></td></tr><tr><td>36</td><td><em>GIPC1</em></td><td>19:14496041-14496074</td><td>Oculopharyngodistal myopathy 2 (OPDM2)</td><td>AD</td><td>CCG</td><td>0–32</td><td>N/A</td><td>33–72</td><td>≥73</td></tr><tr><td>37</td><td><em>GLS</em></td><td>2:190880872-190880920</td><td>Glutaminase deficiency with impaired intellectual development and progressive ataxia (GD)</td><td>AR</td><td>GCA</td><td>0–38</td><td>N/A</td><td>39–679</td><td>≥680</td></tr><tr><td>38</td><td><em>HOXA13_1</em></td><td>7:27199924-27199966</td><td>Hand-foot-genital syndrome (HFG)</td><td>AD</td><td>NGC</td><td>0–14</td><td>N/A</td><td>15–21</td><td>≥22</td></tr><tr><td>39</td><td><em>HOXA13_2</em></td><td>7:27199825-27199861</td><td>Hand-foot-genital syndrome (HFG)</td><td>AD</td><td>NGC</td><td>0–12</td><td>N/A</td><td>13–17</td><td>≥18</td></tr><tr><td>40</td><td><em>HOXA13_3</em></td><td>7:27199678-27199732</td><td>Hand-foot-genital syndrome (HFG)</td><td>AD</td><td>NGC</td><td>0–18</td><td>N/A</td><td>19–21</td><td>≥22</td></tr><tr><td>41</td><td><em>HOXD13</em></td><td>2:176093058-176093103</td><td>Synpolydactyly (SPD)</td><td>AD</td><td>GCG</td><td>0–15</td><td>N/A</td><td>16–21</td><td>≥22</td></tr><tr><td>42</td><td><em>HTT</em></td><td>4:3074876-3074933</td><td>Huntington disease (HD)</td><td>AD</td><td>CAG</td><td>0–26</td><td>27–35</td><td>N/A</td><td>≥36</td></tr><tr><td>43</td><td><em>JPH3</em></td><td>16:87604287-87604329</td><td>Huntington disease-like 2 (HDL2)</td><td>AD</td><td>CTG</td><td>0–28</td><td>N/A</td><td>29–39</td><td>≥40</td></tr><tr><td>44</td><td><em>LRP12</em></td><td>8:104588970-104588997</td><td>Oculopharyngodistal myopathy 1 (OPDM1)</td><td>AD</td><td>CGC</td><td>0–45</td><td>N/A</td><td>46–84</td><td>≥85</td></tr><tr><td>45</td><td><em>MARCHF6</em></td><td>5:10356346-10356411</td><td>Familial adult myoclonic epilepsy 3 (FAME3)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–649<sup>r</sup></td><td>≥650<sup>r</sup></td></tr><tr><td>46</td><td><em>NAXE</em></td><td>1:156591765-156591780</td><td>NAXE-related mitochondrial encephalopathy (NME)</td><td>AR</td><td>GGGCC</td><td>0–7</td><td>N/A</td><td>8–199</td><td>≥200</td></tr><tr><td>47</td><td><em>NIPA1</em></td><td>15:22786677-22786701</td><td>Amyotrophic lateral sclerosis (ALS)</td><td>AD</td><td>GCG</td><td>0–10</td><td>N/A</td><td>N/A</td><td>≥11</td></tr><tr><td>48</td><td><em>NOP56</em></td><td>20:2652733-2652757</td><td>Spinocerebellar ataxia 36 (SCA36)</td><td>AD</td><td>GGCCTG</td><td>0–14</td><td>N/A</td><td>15–649</td><td>≥650</td></tr><tr><td>49</td><td><em>NOTCH2NLA</em></td><td>1:146228800-146228821</td><td>N/A</td><td>N/A</td><td>GCC</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>50</td><td><em>NOTCH2NLC</em></td><td>1:149390802-149390841</td><td>Hereditary essential tremor type 6 (ETM6); Neuronal intranuclear inclusion disease (NIID)</td><td>AD</td><td>GGC</td><td>0–37<sup>s</sup></td><td>N/A</td><td>38–59<sup>s</sup></td><td>≥60<sup>s</sup></td></tr><tr><td>51</td><td><em>NUTM2B-AS1</em></td><td>10:79826383-79826404</td><td>Oculopharyngeal myopathy with leukoencephalopathy 1 (OPML1)</td><td>AD</td><td>GGC</td><td>0–16</td><td>N/A</td><td>17–160</td><td>≥161</td></tr><tr><td>52</td><td><em>PABPN1</em></td><td>14:23321472-23321490</td><td>Oculopharyngeal muscular dystrophy (OPMD)</td><td>AD</td><td>GCG</td><td>0–6</td><td>N/A</td><td>N/A</td><td>≥7</td></tr><tr><td>53</td><td><em>PHOX2B</em></td><td>4:41745972-41746032</td><td>Central hypoventilation syndrome (CCHS)</td><td>AD</td><td>GCN</td><td>0–20</td><td>N/A</td><td>21–25<sup>t</sup></td><td>≥26<sup>t</sup></td></tr><tr><td>54</td><td><em>PPP2R2B</em></td><td>5:146878727-146878757</td><td>Spinocerebellar ataxia 12 (SCA12)</td><td>AD</td><td>GCT</td><td>0–32</td><td>N/A</td><td>33–50</td><td>≥51</td></tr><tr><td>55</td><td><em>PRDM12</em></td><td>9:130681606-130681639</td><td>Hereditary sensory and autonomic neuropathy type 8 (HSAN8)</td><td>AR</td><td>GCC</td><td>0–14</td><td>N/A</td><td>15–17</td><td>≥18</td></tr><tr><td>56</td><td>PRE-MIR7-2</td><td>15:88569433-88569449</td><td>Nongoitrous congenital hypothyroidism-3 (CHNG3)</td><td>AD</td><td>TTTG</td><td>≥4</td><td>N/A</td><td>0–2<sup>u</sup></td><td>3</td></tr><tr><td>57</td><td><em>PRNP</em></td><td>20:4699397-4699493</td><td>Creutzfeldt-Jakob disease (CJD)</td><td>AD</td><td>CCTCATGGTGGTGGCTGGGGGCAG</td><td>0–4</td><td>N/A</td><td>5–8</td><td>≥9</td></tr><tr><td>58</td><td><em>RAPGEF2</em></td><td>4:159342526-159342616</td><td>Familial adult myoclonic epilepsy 7 (FAME7)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–59</td><td>≥60</td></tr><tr><td>59</td><td><em>RFC1</em></td><td>4:39348424-39348479</td><td>Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS)</td><td>AR</td><td>AAAAG</td><td>0–11</td><td>N/A</td><td>12–399</td><td>≥400</td></tr><tr><td>60</td><td><em>RILPL1</em></td><td>12:123533720-123533750</td><td>Oculopharyngodistal myopathy type 4 (OPDM4)</td><td>AD</td><td>GGC</td><td>0–16<sup>v</sup></td><td>N/A</td><td>17–119<sup>v</sup></td><td>≥120</td></tr><tr><td>61</td><td><em>RUNX2</em></td><td>6:45422750-45422792</td><td>Cleidocranial dysplasia (CCD)</td><td>AD</td><td>GCN</td><td>0–17</td><td>N/A</td><td>18–19</td><td>≥20</td></tr><tr><td>62</td><td><em>SAMD12</em></td><td>8:118366810-118366918<sup>w</sup></td><td>Familial adult myoclonic epilepsy 1 (FAME1)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–104<sup>w</sup></td><td>≥105<sup>w</sup></td></tr><tr><td>63</td><td><em>SOX3</em></td><td>X:140504316-140504361</td><td>X-linked mental retardation with isolated growth hormone (XLMR); X-linked panhypopituitarism (PHPX)</td><td>XR</td><td>NGC</td><td>0–15</td><td>N/A</td><td>16–21</td><td>≥22<sup>x</sup></td></tr><tr><td>64</td><td><em>STARD7</em></td><td>2:96197066-96197121</td><td>Familial adult myoclonic epilepsy 2 (FAME2)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–273</td><td>≥274</td></tr><tr><td>65</td><td><em>TBP</em></td><td>6:170561906-170562017</td><td>Spinocerebellar ataxia 17 (SCA17)</td><td>AD</td><td>GCA</td><td>0–40<sup>y</sup></td><td>N/A</td><td>41–48<sup>y</sup></td><td>≥49<sup>y</sup></td></tr><tr><td>66</td><td><em>TBX1</em></td><td>22:19766762-19766807</td><td>Tetralogy of Fallot (TOF)</td><td>AD</td><td>GCN</td><td>0–15</td><td>N/A</td><td>16–24</td><td>≥25</td></tr><tr><td>67</td><td><em>TCF4</em></td><td>18:55586155-55586227</td><td>Fuchs endothelial corneal dystrophy 3 (FECD3)</td><td>AD</td><td>CAG</td><td>0–39</td><td>N/A</td><td>40–49</td><td>≥50</td></tr><tr><td>68</td><td><em>THAP11</em></td><td>16:67842863-67842950</td><td>Spinocerebellar ataxia (SCA)</td><td>AD</td><td>CAG</td><td>0–38</td><td>N/A</td><td>39–44</td><td>≥45</td></tr><tr><td>69</td><td><em>TMEM185A</em></td><td>X:149631735-149631780</td><td>N/A</td><td>N/A</td><td>CGC</td><td>N/A</td><td>N/A</td><td>≥0<sup>a</sup></td><td>N/A</td></tr><tr><td>70</td><td><em>TNRC6A</em></td><td>16:24613438-24613529<sup>z</sup></td><td>Familial adult myoclonic epilepsy 6 (FAME6)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–1099</td><td>≥1100</td></tr><tr><td>71</td><td><em>VWA1</em></td><td>1:1435798-1435818</td><td>Hereditary motor neuropathy (HMN)</td><td>AR</td><td>GGCGCGGAGC</td><td>0–2</td><td>N/A</td><td>N/A</td><td>≥3</td></tr><tr><td>72</td><td><em>XYLT1</em></td><td>16:17470907-17470922</td><td>Desbuquois dysplasia 2 (DBQD2)</td><td>AR</td><td>GCC</td><td>0–20</td><td>N/A</td><td>21–71<sup>aa</sup></td><td>≥72<sup>aa</sup></td></tr><tr><td>73</td><td><em>YEATS2</em></td><td>3:183712187-183712222</td><td>Familial adult myoclonic epilepsy 4 (FAME4)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–999</td><td>≥1000</td></tr><tr><td>74</td><td><em>ZFHX3</em></td><td>16:72787694-72787757</td><td>Spinocerebellar ataxia 4 (SCA4)</td><td>AD</td><td>GCC</td><td>0–26</td><td>N/A</td><td>27–45<sup>bb</sup></td><td>≥46<sup>bb</sup></td></tr><tr><td>75</td><td><em>ZIC2</em></td><td>13:99985448-99985493</td><td>Holoprosencephaly 5 (HPE5)</td><td>AD</td><td>GCN</td><td>0–15</td><td>N/A</td><td>16–24</td><td>≥25</td></tr><tr><td>76</td><td><em>ZIC3</em></td><td>X:137566826-137566856</td><td>X-linked VACTERL syndrome (VACTERLX)</td><td>XR</td><td>GCC</td><td>0–10</td><td>N/A</td><td>11</td><td>≥12</td></tr><tr><td>77</td><td><em>ZNF713</em></td><td>7:55887600-55887639</td><td>N/A</td><td>N/A</td><td>GCG</td><td>N/A</td><td>N/A</td><td>0–449<sup>a</sup></td><td>≥450<sup>a</sup></td></tr></tbody></table>

N/A: not applicable.

<sup>a</sup> gnomAD gives no repeat-count ranges for this locus.

<sup>b</sup> gnomAD gives a normal range of up to 35 repeats and a pathogenic threshold of 38.

<sup>c</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 17 repeats for MRXARX and 23 for DEE1. Emedgene uses the lower threshold.

<sup>d</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 20 repeats for DEE1 and PRTS, and 23 for MRXARX. Emedgene uses the lower threshold.

<sup>e</sup> gnomAD gives a normal range of up to 32 repeats and an intermediate range of 30–799, which overlap.

<sup>f</sup> gnomAD gives a normal range of up to 31 repeats and an intermediate range of 32–34.

<sup>g</sup> In gnomAD, this locus starts 1 base later, and the pathogenic threshold is 56 repeats.

<sup>h</sup> gnomAD gives a normal range of up to 33 repeats.

<sup>i</sup> gnomAD gives a normal range of up to 50 repeats, an intermediate range of 38–79, and a pathogenic threshold of 71, which overlap.

<sup>j</sup> gnomAD gives an intermediate count of 19 repeats and a pathogenic threshold of 20.

<sup>k</sup> gnomAD gives a normal range of up to 54 repeats and a pathogenic threshold of 55.

<sup>l</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 6 repeats for EDM1 and 7 for PSACH. Emedgene uses the lower threshold.

<sup>m</sup> gnomAD gives only a pathogenic threshold of 31 repeats.

<sup>n</sup> gnomAD gives a normal range of up to 11 repeats and a pathogenic threshold of 14.

<sup>o</sup> In gnomAD, this locus starts 2 bases earlier. gnomAD gives a normal range of up to 250 repeats, an intermediate range of 250–335, and a pathogenic threshold of 320, which overlap.

<sup>p</sup> gnomAD gives a normal range of up to 44 repeats, which overlaps its intermediate range of 41–54, and a pathogenic threshold for each condition: 55 repeats for FXTAS and 201 for FXS. Emedgene uses the lower threshold.

<sup>q</sup> gnomAD gives a pathogenic threshold of 66 repeats.

<sup>r</sup> gnomAD gives a pathogenic threshold of 668 repeats.

<sup>s</sup> gnomAD gives separate ranges for each condition at this locus: for NIID, normal up to 39 repeats and pathogenic from 90; for ETM6, normal up to 41 and pathogenic from 60. Emedgene uses the lower pathogenic threshold.

<sup>t</sup> gnomAD gives a pathogenic threshold of 24 repeats.

<sup>u</sup> gnomAD gives a pathogenic count of 3 repeats and a normal range from 4 repeats, and no range below 3.

<sup>v</sup> gnomAD gives a normal range of up to 20 repeats.

<sup>w</sup> In gnomAD, this locus starts 2 bases later, and the pathogenic threshold is 100 repeats.

<sup>x</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 22 repeats for PHPX and 26 for XLMR. Emedgene uses the lower threshold.

<sup>y</sup> gnomAD gives a normal range of up to 42 repeats and a pathogenic threshold of 43.

<sup>z</sup> In gnomAD, this locus starts 1 base later.

<sup>aa</sup> gnomAD gives a pathogenic threshold of 110 repeats.

<sup>bb</sup> gnomAD gives a pathogenic threshold of 41 repeats.

***

## gnomAD STR loci (v100.40 and earlier)

Table 2 lists the loci that Emedgene annotates with gnomAD pathogenicity data on v100.40 and earlier, with the repeat-count range for each significance class.

The start positions and repeat-count ranges are the values Emedgene used. The other columns are from gnomAD STR release 2022\_01\_20. Where Emedgene's value differs from gnomAD, a footnote gives the gnomAD value.

**Table 2. STR loci annotated with gnomAD pathogenicity data (v100.40 and earlier).**

<table data-header-hidden="false" data-header-sticky data-full-width="true"><thead><tr><th width="43" data-type="number">№</th><th width="68">STR locus</th><th width="94">Genomic region (GRCh38)</th><th>Associated condition(s)</th><th width="99">Inheritance mode</th><th width="71">Repeat unit</th><th>Benign</th><th width="114">VUS</th><th>Other</th><th>Pathogenic</th></tr></thead><tbody><tr><td>1</td><td><em>AFF2</em></td><td>X:148500631-148500691</td><td>FRAXE mental retardation (FRAXE)</td><td>XR</td><td>GCC</td><td>0–25</td><td>N/A</td><td>26–199</td><td>≥200</td></tr><tr><td>2</td><td><em>AR</em></td><td>X:67545316-67545385</td><td>Spinal and bulbar muscular atrophy (SBMA)</td><td>XR</td><td>GCA</td><td>0–35</td><td>N/A</td><td>36–39</td><td>≥40</td></tr><tr><td>3</td><td><em>ARX_1</em></td><td>X:25013649-25013697</td><td>Developmental and epileptic encephalopathy-1 (DEE1); X-linked mental retardation with or without seizures (MRXARX)</td><td>XR</td><td>NGC</td><td>0–16</td><td>N/A</td><td>17</td><td>≥18<sup>a</sup></td></tr><tr><td>4</td><td><em>ARX_2</em></td><td>X:25013529-25013565</td><td>Developmental and epileptic encephalopathy 1 (DEE1); Partington syndrome (PRTS); X-linked mental retardation with or without seizures (MRXARX)</td><td>XR</td><td>NGC</td><td>0–12</td><td>N/A</td><td>13–19</td><td>≥20<sup>b</sup></td></tr><tr><td>5</td><td><em>ATN1</em></td><td>12:6936716-6936773</td><td>Dentatorubral-pallidoluysian atrophy (DRPLA)</td><td>AD</td><td>CAG</td><td>0–23</td><td>N/A</td><td>24–48</td><td>≥49</td></tr><tr><td>6</td><td><em>ATXN1</em></td><td>6:16327633-16327723</td><td>Spinocerebellar ataxia 1 (SCA1)</td><td>AD</td><td>TGC</td><td>0–32</td><td>36–38</td><td>33–35</td><td>≥39</td></tr><tr><td>7</td><td><em>ATXN10</em></td><td>22:45795354-45795424</td><td>Spinocerebellar ataxia 10 (SCA10)</td><td>AD</td><td>ATTCT</td><td>0–29</td><td>30–799</td><td>N/A</td><td>≥800</td></tr><tr><td>8</td><td><em>ATXN2</em></td><td>12:111598949-111599018</td><td>Spinocerebellar ataxia 2 (SCA2)</td><td>AD</td><td>GCT</td><td>0–31</td><td>32–34</td><td>N/A</td><td>≥35</td></tr><tr><td>9</td><td><em>ATXN3</em></td><td>14:92071009-92071042</td><td>Spinocerebellar ataxia 3 (SCA3)</td><td>AD</td><td>GCT</td><td>0–44</td><td>45–55</td><td>N/A</td><td>≥56</td></tr><tr><td>10</td><td><em>ATXN7</em></td><td>3:63912684-63912714</td><td>Spinocerebellar ataxia 7 (SCA7)</td><td>AD</td><td>GCA</td><td>0–33</td><td>34–36</td><td>N/A</td><td>≥37</td></tr><tr><td>11</td><td><em>ATXN8OS</em></td><td>13:70139383-70139428</td><td>Spinocerebellar ataxia 8 (SCA8)</td><td>AD</td><td>CTG</td><td>0–37</td><td>38–79</td><td>N/A</td><td>≥80</td></tr><tr><td>12</td><td><em>BEAN1</em></td><td>16:66490398-66490452<sup>c</sup></td><td>Spinocerebellar ataxia 31 (SCA31)</td><td>AD</td><td>TAAAA</td><td>N/A</td><td>N/A</td><td>0–499</td><td>≥500</td></tr><tr><td>13</td><td><em>C9ORF72</em></td><td>9:27573528-27573546</td><td>Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 (FTDALS1)</td><td>AD</td><td>GGCCCC</td><td>0–23</td><td>N/A</td><td>24–30</td><td>≥31</td></tr><tr><td>14</td><td><em>CACNA1A</em></td><td>19:13207858-13207897</td><td>Spinocerebellar ataxia 6 (SCA6)</td><td>AD</td><td>CTG</td><td>0–18</td><td>19</td><td>20</td><td>≥21</td></tr><tr><td>15</td><td><em>CNBP</em></td><td>3:129172576-129172656</td><td>Myotonic dystrophy 2 (DM2)</td><td>AD</td><td>CAGG</td><td>0–54</td><td>N/A</td><td>N/A</td><td>≥55</td></tr><tr><td>16</td><td><em>COMP</em></td><td>19:18786034-18786049</td><td>Multiple epiphyseal dysplasia (EDM1); Pseudoachondroplasia (PSACH)</td><td>AD</td><td>GTC</td><td>N/A</td><td>N/A</td><td>0–5</td><td>≥6<sup>d</sup></td></tr><tr><td>17</td><td><em>CSTB</em></td><td>21:43776443-43776479</td><td>Epilepsy Progressive Myoclonic (EPM1)</td><td>AR</td><td>CGCGGGGCGGGG</td><td>N/A</td><td>N/A</td><td>0–29</td><td>≥30</td></tr><tr><td>18</td><td><em>DAB1</em></td><td>1:57367043-57367118<sup>c</sup></td><td>Spinocerebellar ataxia 37 (SCA37)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–30</td><td>≥31</td></tr><tr><td>19</td><td><em>DIP2B</em></td><td>12:50505001-50505022</td><td>Mental retardation, FRA12A type (MRFRA12A)</td><td>AD</td><td>GGC</td><td>0–23</td><td>N/A</td><td>24–149</td><td>≥150</td></tr><tr><td>20</td><td><em>DMD</em></td><td>X:31284557-31284605</td><td>Duchenne muscular dystrophy (DMD)</td><td>XR</td><td>TTC</td><td>0–33</td><td>N/A</td><td>34–58</td><td>≥59</td></tr><tr><td>21</td><td><em>DMPK</em></td><td>19:45770204-45770264</td><td>Myotonic dystrophy 1 (DM1)</td><td>AD</td><td>CAG</td><td>0–34</td><td>35–49</td><td>N/A</td><td>≥50</td></tr><tr><td>22</td><td><em>EIF4A3</em></td><td>17:80147059-80147139</td><td>Richieri-Costa-Pereira syndrome (RCPS)</td><td>AR</td><td>CCTCGCTGTGCCGCTGCCGA</td><td>N/A</td><td>N/A</td><td>0–13</td><td>≥14</td></tr><tr><td>23</td><td><em>FMR1</em></td><td>X:147912050-147912110</td><td>Fragile X tremor/ataxia syndrome (FXTAS); Fragile X Syndrome (FXS)</td><td>XD</td><td>CGG</td><td>0–40</td><td>41–54</td><td>N/A</td><td>≥55<sup>e</sup></td></tr><tr><td>24</td><td><em>FOXL2</em></td><td>3:138946020-138946062</td><td>Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES)</td><td>AD</td><td>NGC</td><td>0–14</td><td>N/A</td><td>15–18</td><td>≥19</td></tr><tr><td>25</td><td><em>FXN</em></td><td>9:69037286-69037304</td><td>Friedreich ataxia (FRDA)</td><td>AR</td><td>GAA</td><td>0–30</td><td>N/A</td><td>31–69</td><td>≥70</td></tr><tr><td>26</td><td><em>GIPC1</em></td><td>19:14496041-14496074</td><td>Oculopharyngodistal myopathy 2 (OPDM2)</td><td>AD</td><td>CCG</td><td>0–32</td><td>N/A</td><td>33–72</td><td>≥73</td></tr><tr><td>27</td><td><em>GLS</em></td><td>2:190880872-190880920</td><td>Glutaminase deficiency with impaired intellectual development and progressive ataxia (GD)</td><td>AR</td><td>GCA</td><td>0–26</td><td>N/A</td><td>27–679</td><td>≥680</td></tr><tr><td>28</td><td><em>HOXA13_1</em></td><td>7:27199924-27199966</td><td>Hand-foot-genital syndrome (HFG)</td><td>AD</td><td>NGC</td><td>0–14</td><td>N/A</td><td>15–21</td><td>≥22</td></tr><tr><td>29</td><td><em>HOXA13_2</em></td><td>7:27199825-27199861</td><td>Hand-foot-genital syndrome (HFG)</td><td>AD</td><td>NGC</td><td>0–12</td><td>N/A</td><td>13–17</td><td>≥18</td></tr><tr><td>30</td><td><em>HOXA13_3</em></td><td>7:27199678-27199732</td><td>Hand-foot-genital syndrome (HFG)</td><td>AD</td><td>NGC</td><td>0–18</td><td>N/A</td><td>19–23</td><td>≥24</td></tr><tr><td>31</td><td><em>HOXD13</em></td><td>2:176093058-176093103</td><td>Synpolydactyly (SPD)</td><td>AD</td><td>GCG</td><td>0–15</td><td>N/A</td><td>16–21</td><td>≥22</td></tr><tr><td>32</td><td><em>HTT</em></td><td>4:3074876-3074933</td><td>Huntington disease (HD)</td><td>AD</td><td>CAG</td><td>0–26</td><td>27–35</td><td>N/A</td><td>≥36</td></tr><tr><td>33</td><td><em>JPH3</em></td><td>16:87604287-87604329</td><td>Huntington disease-like 2 (HDL2)</td><td>AD</td><td>CTG</td><td>0–27</td><td>N/A</td><td>28–40</td><td>≥41</td></tr><tr><td>34</td><td><em>LRP12</em></td><td>8:104588970-104588997</td><td>Oculopharyngodistal myopathy 1 (OPDM1)</td><td>AD</td><td>CGC</td><td>0–45</td><td>N/A</td><td>46–92</td><td>≥93</td></tr><tr><td>35</td><td><em>MARCHF6</em></td><td>5:10356346-10356411<sup>c</sup></td><td>Familial adult myoclonic epilepsy 3 (FAME3)</td><td>AD</td><td>ATTTT</td><td>N/A</td><td>N/A</td><td>0–667</td><td>≥668</td></tr><tr><td>36</td><td><em>NIPA1</em></td><td>15:22786677-22786701</td><td>Amyotrophic lateral sclerosis (ALS)</td><td>AD</td><td>GCG</td><td>0–10</td><td>N/A</td><td>N/A</td><td>≥11</td></tr><tr><td>37</td><td><em>NOP56</em></td><td>20:2652733-2652757</td><td>Spinocerebellar ataxia 36 (SCA36)</td><td>AD</td><td>GGCCTG</td><td>0–14</td><td>N/A</td><td>15–649</td><td>≥650</td></tr><tr><td>38</td><td><em>NOTCH2NLC</em></td><td>1:149390802-149390841</td><td>Hereditary essential tremor type 6 (ETM6); Neuronal intranuclear inclusion disease (NIID)</td><td>AD</td><td>GGC</td><td>0–39<sup>f</sup></td><td>N/A</td><td>40–59</td><td>≥60<sup>f</sup></td></tr><tr><td>39</td><td><em>NUTM2B-AS1</em></td><td>10:79826383-79826404</td><td>Oculopharyngeal myopathy with leukoencephalopathy 1 (OPML1)</td><td>AD</td><td>GGC</td><td>0–16</td><td>N/A</td><td>17–699</td><td>≥700</td></tr><tr><td>40</td><td><em>PABPN1</em></td><td>14:23321472-23321490</td><td>Oculopharyngeal muscular dystrophy (OPMD)</td><td>AD</td><td>GCG</td><td>0–6</td><td>N/A</td><td>N/A</td><td>≥7</td></tr><tr><td>41</td><td><em>PHOX2B</em></td><td>4:41745972-41746032</td><td>Central hypoventilation syndrome (CCHS)</td><td>AD</td><td>GCN</td><td>0–20</td><td>N/A</td><td>21–23</td><td>≥24</td></tr><tr><td>42</td><td><em>PPP2R2B</em></td><td>5:146878727-146878757</td><td>Spinocerebellar ataxia 12 (SCA12)</td><td>AD</td><td>GCT</td><td>0–31</td><td>N/A</td><td>32–50</td><td>≥51</td></tr><tr><td>43</td><td><em>PRDM12</em></td><td>9:130681606-130681639</td><td>Hereditary sensory and autonomic neuropathy type VIII (HSAN8)</td><td>AR</td><td>GCC</td><td>0–14</td><td>N/A</td><td>15–17</td><td>≥18</td></tr><tr><td>44</td><td><em>PRNP</em></td><td>20:4699397-4699493</td><td>Creutzfeldt-Jakob disease (CJD)</td><td>AD</td><td>CCTCATGGTGGTGGCTGGGGGCAG</td><td>0–4</td><td>N/A</td><td>N/A</td><td>≥5</td></tr><tr><td>45</td><td><em>RAPGEF2</em></td><td>4:159342526-159342616<sup>c</sup></td><td>Familial adult myoclonic epilepsy 7 (FAME7)</td><td>AD</td><td>TTTTA</td><td>N/A</td><td>N/A</td><td>0–59</td><td>≥60</td></tr><tr><td>46</td><td><em>RFC1</em></td><td>4:39348424-39348479<sup>c</sup></td><td>Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS)</td><td>AR</td><td>AAAAG</td><td>N/A</td><td>N/A</td><td>0–399</td><td>≥400</td></tr><tr><td>47</td><td><em>RUNX2</em></td><td>6:45422750-45422792</td><td>Cleidocranial dysplasia (CCD)</td><td>AD</td><td>GCN</td><td>0–17</td><td>N/A</td><td>18–26</td><td>≥27</td></tr><tr><td>48</td><td><em>SAMD12</em></td><td>8:118366815-118366880<sup>c</sup></td><td>Familial adult myoclonic epilepsy 1 (FAME1)</td><td>AD</td><td>TAAAA</td><td>N/A</td><td>N/A</td><td>0–99</td><td>≥100</td></tr><tr><td>49</td><td><em>SOX3</em></td><td>X:140504316-140504361</td><td>X-linked mental retardation with isolated growth hormone (XLMR); X-linked panhypopituitarism (PHPX)</td><td>XR</td><td>NGC</td><td>0–15</td><td>N/A</td><td>16–21</td><td>≥22<sup>g</sup></td></tr><tr><td>50</td><td><em>STARD7</em></td><td>2:96197066-96197121<sup>c</sup></td><td>Familial adult myoclonic epilepsy 2 (FAME2)</td><td>AD</td><td>AAAAT</td><td>N/A</td><td>N/A</td><td>0–273</td><td>≥274</td></tr><tr><td>51</td><td><em>TBP</em></td><td>6:170561906-170562017</td><td>Spinocerebellar ataxia 17 (SCA17)</td><td>AD</td><td>GCA</td><td>0–42</td><td>N/A</td><td>N/A</td><td>≥43</td></tr><tr><td>52</td><td><em>TBX1</em></td><td>22:19766762-19766807</td><td>Tetralogy of Fallot (TOF)</td><td>AD</td><td>GCN</td><td>0–15</td><td>N/A</td><td>16–24</td><td>≥25</td></tr><tr><td>53</td><td><em>TCF4</em></td><td>18:55586155-55586227</td><td>Fuchs endothelial corneal dystrophy-3 (FECD3)</td><td>AD</td><td>CAG</td><td>0–31</td><td>N/A</td><td>32–49</td><td>≥50</td></tr><tr><td>54</td><td><em>TNRC6A</em></td><td>16:24613439-24613529<sup>c</sup></td><td>Familial adult myoclonic epilepsy 6 (FAME6)</td><td>AD</td><td>TTTTA</td><td>N/A</td><td>N/A</td><td>0–1099</td><td>≥1100</td></tr><tr><td>55</td><td><em>VWA1</em></td><td>1:1435798-1435818</td><td>Hereditary motor neuropathy (HMN)</td><td>AR</td><td>GGCGCGGAGC</td><td>0–2</td><td>N/A</td><td>N/A</td><td>≥3</td></tr><tr><td>56</td><td><em>XYLT1</em></td><td>16:17470907-17470922</td><td>Desbuquois dysplasia-2 (DBQD2)</td><td>AR</td><td>GCC</td><td>0–20</td><td>N/A</td><td>21–109</td><td>≥110</td></tr><tr><td>57</td><td><em>YEATS2</em></td><td>3:183712187-183712222<sup>c</sup></td><td>Familial adult myoclonic epilepsy 4 (FAME4)</td><td>AD</td><td>TTTTA</td><td>N/A</td><td>N/A</td><td>0–999</td><td>≥1000</td></tr><tr><td>58</td><td><em>ZIC2</em></td><td>13:99985448-99985493</td><td>Holoprosencephaly 5 (HPE5)</td><td>AD</td><td>GCN</td><td>0–15</td><td>N/A</td><td>16–24</td><td>≥25</td></tr><tr><td>59</td><td><em>ZIC3</em></td><td>X:137566826-137566856</td><td>X-linked VACTERL syndrome (VACTERLX)</td><td>XR</td><td>GCN</td><td>0–10</td><td>N/A</td><td>11</td><td>≥12</td></tr></tbody></table>

N/A: not applicable.

<sup>a</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 18 repeats for MRXARX and 23 for DEE1. Emedgene uses the lower threshold.

<sup>b</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 20 repeats for DEE1 and PRTS, and 23 for MRXARX. Emedgene uses the lower threshold.

<sup>c</sup> In gnomAD, this locus starts 1 base later.

<sup>d</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 6 repeats for EDM1 and 7 for PSACH. Emedgene uses the lower threshold.

<sup>e</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 55 repeats for FXTAS and 201 for FXS. Emedgene uses the lower threshold.

<sup>f</sup> gnomAD gives separate ranges for each condition at this locus: for NIID, normal up to 39 repeats and pathogenic from 90; for ETM6, normal up to 41 and pathogenic from 60. Emedgene uses the lower value of each.

<sup>g</sup> gnomAD gives a pathogenic threshold for each condition at this locus: 22 repeats for PHPX and 26 for XLMR. Emedgene uses the lower threshold.

***

## Learn more

<table data-view="cards"><thead><tr><th></th><th></th><th></th></tr></thead><tbody><tr><td><strong>Tertiary analysis of STR variants</strong></td><td>How STR variants are called, filtered, annotated, and prioritized.</td><td><i class="fa-arrow-up-right-from-square">:arrow-up-right-from-square:</i> <a href="https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation.md">Learn more</a></td></tr><tr><td><strong>STR loci considered by AI Shortlist</strong></td><td>The genes that AI Shortlist considers for STR variants, with the disease-associated locus for each.</td><td><i class="fa-arrow-up-right-from-square">:arrow-up-right-from-square:</i> <a href="https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation/str-loci-considered-by-ai-shortlist.md">Learn more</a></td></tr><tr><td><strong>Versions tab</strong></td><td>Versions of the tools, data sources, and knowledge bases used to analyze a case.</td><td><i class="fa-arrow-up-right-from-square">:arrow-up-right-from-square:</i> <a href="https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/reviewing_a_case/versions_tab.md">Learn more</a></td></tr></tbody></table>


---

# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.

## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation by asking a question.

Perform an HTTP GET request on the following URL with the `ask` and `goal` query parameters:

```
GET https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation/str-loci-annotated-with-gnomad-pathogenicity-data.md?ask=<question>&goal=<user_goal>
```

`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is what the user is ultimately trying to achieve, the reason they need the answer. Sharing it helps GitBook give you a better, more relevant answer. A goal is most helpful when it describes the outcome the user wants rather than restating the question. For example, with `ask=how do I create an API token`, a goal like `automate deployments from our CI pipeline` lets GitBook tailor the answer to that use case.

The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.
